HomepageMVIR • STO
add
Medivir AB
Vorige slotkoers
kr 1,39
Dag-range
kr 1,34 - kr 1,50
Jaar-range
kr 1,25 - kr 3,99
Beurswaarde
150,30Â mln. SEK
Gem. volume
493,00K
Koers/winst
-
Dividendrendement
-
Primaire beurs
STO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (SEK) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,00Â mln. | -77,44% |
Bedrijfskosten | 7,70Â mln. | -13,69% |
Netto inkomsten | -26,70Â mln. | -32,03% |
Netto winstmarge | -2,67K | -485,31% |
Winst per aandeel | -0,23 | 17,86% |
EBITDA | -26,60Â mln. | -31,34% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (SEK) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 62,50Â mln. | -63,13% |
Totale activa | 172,60Â mln. | -40,05% |
Totale passiva | 57,10Â mln. | -18,41% |
Totaal aandelenvermogen | 115,50 mln. | — |
Uitstaande aandelen | 112,17 mln. | — |
Koers-boekwaardeverhouding | 1,35 | — |
Rendement op activa | -36,23% | — |
Rendement op kapitaal | -49,56% | — |
Kasstroom
Nettomutatie in liquide middelen
| (SEK) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -26,70Â mln. | -32,03% |
Operationele kasstroom | -29,40Â mln. | -544,03% |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | -600,00K | -100,53% |
Nettomutatie in liquide middelen | -30,10Â mln. | -127,77% |
Vrije kasstroom | -19,86Â mln. | -20.974,27% |
Over
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Opgericht
1988
Website
Werknemers
10
